UBS Upgrades Regeneron Pharmaceuticals (REGN) on Next-Gen Dupixent Potential

gurufocus.com · 2026-10-14

On October 14, 2026, UBS upgraded Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to a Buy rating, citing undervaluation in the market related to the company's pro

TickrTrends take: UBS has upgraded Regeneron Pharmaceuticals based on potential from next-generation versions of its Dupixent product, which represents a meaningful catalyst for the company's pipeline. Given that TickrTrends currently rates REGN as fairly valued, investors should monitor whether the analyst upgrade translates into commercial success that could justify a higher valuation multiple. The execution risk on next-generation drug candidates and their competitive positioning within the dermatology and immunology markets will be key factors for assessing whether the current valuation adequately reflects this new growth opportunity.

Read the full story at gurufocus.com →